Seven Fleet Capital Management LP Takes Position in MBX Biosciences, Inc. $MBX

Seven Fleet Capital Management LP bought a new stake in shares of MBX Biosciences, Inc. (NASDAQ:MBX) during the 4th quarter, HoldingsChannel.com reports. The fund bought 18,200 shares of the company’s stock, valued at approximately $574,000.

Several other institutional investors have also bought and sold shares of the stock. Invesco Ltd. lifted its stake in MBX Biosciences by 79.9% during the 4th quarter. Invesco Ltd. now owns 21,203 shares of the company’s stock valued at $669,000 after acquiring an additional 9,415 shares in the last quarter. KVP Capital Advisors LP purchased a new position in MBX Biosciences during the 4th quarter worth $3,833,000. Opaleye Management Inc. grew its position in MBX Biosciences by 2.8% in the 4th quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock worth $8,200,000 after purchasing an additional 7,000 shares in the last quarter. Elmind Capital LP bought a new position in shares of MBX Biosciences in the fourth quarter valued at approximately $6,655,000. Finally, Balyasny Asset Management L.P. increased its position in shares of MBX Biosciences by 366.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 119,726 shares of the company’s stock valued at $3,776,000 after purchasing an additional 94,085 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Truist Financial boosted their target price on MBX Biosciences from $50.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Barclays increased their target price on MBX Biosciences from $66.00 to $70.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Lifesci Capital raised MBX Biosciences to a “strong-buy” rating in a report on Tuesday, March 31st. Citizens Jmp lifted their price target on MBX Biosciences from $76.00 to $86.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MBX Biosciences in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, MBX Biosciences presently has an average rating of “Moderate Buy” and an average target price of $60.22.

MBX Biosciences Price Performance

Shares of NASDAQ:MBX opened at $43.03 on Friday. The company’s fifty day moving average price is $33.22 and its 200-day moving average price is $33.20. MBX Biosciences, Inc. has a one year low of $9.43 and a one year high of $45.85. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -19.47 and a beta of 0.75.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.